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Abstract The use of low-density lipoprotein cholesterol
(LDL-C)-lowering medications has led to a significant
reduction of cardiovascular risk in both primary and sec-
ondary prevention. Statin therapy, one of the cornerstones
for the prevention and treatment of cardiovascular disease
(CVD), has been demonstrated to be effective in lowering
LDL-C levels and in reducing the risk for CVD and is gen-
erally well-tolerated. However, compliance with statins
remains suboptimal. One of the main reasons is limitations
by adverse events, notably myopathies, which can lead to
non-compliance with the prescribed statin regimen. Reduc-
ing the burden of elevated LDL-C levels is critical in patients
withCVDaswell as in patientswith very high baseline levels
of LDL-C (e.g. patients with familial hypercholestero-
laemia), as statin therapy is insufficient for optimally
reducing LDL-C below target values. In this review, we
discuss alternative treatment options after maximally
tolerated doses of statin therapy, including ezetimibe, pro-
protein convertase subtilisin/kexin type 9 (PCSK9) inhibi-
tors, and cholesteryl ester transfer protein (CETP) inhibitors.
Difficult-to-treat patients may benefit from combination
therapywith ezetimibe or a PCSK9 inhibitor (evolocumab or
alirocumab, which are now available). Updates of treatment
guidelines are needed to guide the management of patients
who will best benefit from these new treatments.
Key Points
Although statins have proven to be a valuable and
efficacious low-density lipoprotein cholesterol
(LDL-C)-lowering medication, they may not be
sufficient or appropriate for every patient in need.
Some patients may benefit from additional or
alternative approaches for LDL-C lowering,
particularly those with familial
hypercholesterolaemia and other patients in whom
LDL-C lowering is not sufficient or who are
intolerant to statins.
Alternative therapies should be considered for
patients who do not reach their LDL-C target, for
example, ezetimibe or proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors.
1 Introduction
Cardiovascular disease (CVD) is the main cause of death in
Europe, accounting for over 4 million deaths each year [1].
Nearly half (47 %) of all deaths are from CVD (52 % of
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deaths in women and 42 % in men). Just under half of all
deaths from CVD in both men and women are from
coronary heart disease (CHD), while stroke accounts for
nearly one-third of deaths in women and one-quarter of
deaths in men [1]. CVD has major economic and human
costs: overall, it is estimated to cost the EU economy
almost €196 billion a year. Of the total cost of CVD in the
EU, around 54 % is due to direct healthcare costs, 24 % to
productivity losses, and 22 % to the informal care of
people with CVD [1].
The role of low-density lipoprotein cholesterol (LDL-C)
in the pathophysiology of CVD is acknowledged and well-
understood, and the use of LDL-C-lowering medications
has led to a significant reduction of cardiovascular risk in
both primary and secondary prevention. Notably, statin
therapy has become a cornerstone for the prevention and
treatment of CVD, and is generally safe and well-tolerated
[2]. A number of large-scale clinical trials have demon-
strated that statins substantially reduce cardiovascular
morbidity and mortality in both primary and secondary
prevention [3–7] and in high-risk patients [8]. Statins have
also been shown to slow the progression or even promote
regression of coronary atherosclerosis [9].
However, compliance remains suboptimal, even though
long-term persistence with statin therapy is important for
clinical benefits [10]. Moreover, in many patients, treat-
ment with statin therapy is insufficient to optimally reduce
LDL-C below target values. The most important reasons
are very high baseline levels of LDL-C, for example in
patients with familial hypercholesterolaemia (FH), and that
the adverse effects of statin therapy can pose limitations,
notably myopathies, which can lead to non-compliance
with the prescribed statin regimen. Reducing the burden of
elevated LDL-C levels is critical in these difficult-to-treat
patient groups and there is a need for new treatment options
and/or combination therapies that ultimately translate into
improved clinical outcomes.
2 Treatment Aims and Low-Density Lipoprotein
Cholesterol (LDL-C) Targets
LDL-C is the primary target of dyslipidemia management; it
is tightly linked to outcomes and is therefore a reliable and
widely used surrogate parameter. The 2010 Cholesterol
Treatment Trialists’ (CTT) Collaboration meta-analysis,
which included 21 randomized trials of statin versus control
in almost 130,000 patients and five trials of more versus less
intensive statin regimens in almost 40,000 patients, con-
firmed a dose-dependent reduction in CVD with LDL-C
lowering [3]. Among available statin therapies, more
intensive regimens resulted in a significant further propor-
tional 15 % risk reduction in major vascular events
associated with the mean 0.51 mmol/l further LDL-C
reduction. In the meta-analysis of statin versus control, there
was a significant risk reduction of 22 % with a 1.00 mmol/l
LDL-C reduction. The most recent CTT meta-analysis,
which focused on whether statin therapy is as effective in
women as in men, found similar effectiveness for the pre-
vention of major vascular events in both groups [5].
Target levels of LDL-C are defined by the patient’s
cardiovascular risk. All current guidelines on the preven-
tion of CVD in clinical practice recommend the assessment
of clinically manifest atherosclerotic CVD and cardiovas-
cular risk because, in most people, atherosclerotic CVD is
the product of a number of risk factors [2]. In primary
prevention, many risk assessment systems are available,
including Framingham, Systemic Coronary Risk Estima-
tion (SCORE), Q-Risk, Prospective Cardiovascular Mun-
ster Study (PROCAM), the American Heart Association
(AHA)/American College of Cardiology (ACC) Pooled
Cohort Equations, and the World Health Organization
(WHO) [11–13]. Most guidelines use risk estimation sys-
tems based on either the Framingham or the SCORE pro-
jects [2, 14, 15]. The SCORE system estimates the 10-year
risk of a first fatal atherosclerotic event, whether heart
attack, stroke, or other occlusive arterial disease, including
sudden cardiac death. According to the European guideli-
nes [2], the presence of atherosclerotic CVD, e.g. a history
of acute myocardial infarction or stroke (i.e. secondary
prevention), defines an LDL-C target\1.8 mmol/l (70 mg/
dl). In primary prevention of patients with diabetes mellitus
(T2DM), FH, or multiple risk factors leading to the esti-
mation of high cardiovascular risk, an LDL-C level
\2.6 mmol/l (100 mg/dl) should be targeted. If these
absolute treatment goals are not reached, LDL-C levels
should be at least halved.
The recent American guidelines (AHA/ACC 2013) no
longer foresee any absolute target levels of LDL-C, but
recommend using high-intensity statin treatment to reduce
LDL-C levels by C50 % in patients with manifest
atherosclerotic disease or high estimated risk, and to reduce
LDL-C levels by 30–50 % in patients with moderate risk.
Their new Pooled Cohort Equations risk calculator results
in a larger population qualifying for treatment with statins,
which has been a matter of debate [16, 17]. If more patients
commence statin therapy because of an overestimated risk,
this might be a reason for more cases of statin non-ad-
herence due to treatment-related adverse effects [18].
3 Statin Non-Adherence and Intolerance
Despite the evidence that low adherence to statins is linked
with worsening outcomes [19–21], numerous studies have
documented high rates of non-adherence to statins [22, 23].
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It is estimated that about half of patients discontinue statin
therapy within the first year of treatment, with further
decreases in adherence over time [24]. There are many
reasons for non-adherence, including age, sex, income,
comorbidities, and complexity of regimen [24]. Using clin-
ical judgment alone, physicians are poor at identifying
which patients have problems with adherence [25]. From a
patient perspective, concerns about the adverse effects of
statins are a dominant theme [26, 27]. Statin-related adverse
effects include mainly muscle symptoms, but also headache,
sleep disorders, dyspepsia, nausea, rash, alopecia, erectile
dysfunction, gynecomastia, and/or arthritis [28]. Statin use
has also been associated with an increased risk of T2DM
[29–31]. Additionally, disparities in lipid control among
patients with T2DM using statins have been reported [32].
Data reported from the PINNACLE registry showed that
patients with T2DM were less likely to achieve LDL-C and
non-high-density lipoprotein cholesterol (non-HDL-C) goals
than other patients with dyslipidemia. Goals were not
achieved for nearly 70 % of patients [33].
Most common adverse effects associated with statins are
muscle related [28], and the most recent statement from the
European Atherosclerosis Society (EAS) uses the term
statin-associated muscle symptoms (SAMS) [34]. SAMS
are one of the principal reasons for statin non-adherence
and/or discontinuation, contributing to adverse cardiovas-
cular outcomes [34].
The clinical features of SAMS include symptoms such
as muscle aches or myalgia, weakness, stiffness, and
cramps [35]. SAMS are usually defined as diffuse muscle
symptoms that may or may not be accompanied by an
elevation of plasma creatinine kinase (CK) activity
[35, 36]. Rhabdomyolysis is a more severe form of statin-
induced myopathy (usually associated with CK elevations
[10 times the upper limit of normal [ULN]), resulting in
severe skeletal muscle injury, lysis, and excretion of dark
brown urine, indicating the presence of excess myoglobin
and leading to kidney damage [37, 38].
It is estimated that SAMS occur in 2–6 % of the statin
population (affecting about 1 million patients) [39] based
on real-world data, the incidence rate of SAMS is
approximately 5–10 % [40, 41]. Patient registries and
clinical experience estimate the incidence of SAMS at
between 7 and 29 %, and these may be an important con-
tributor to the very high discontinuation rates observed
with statin therapy [34, 40, 42–45]. In their investigation of
long-term persistence with statin treatment, Chodick et al.
[10] found that C75 % of patients discontinued therapy
within 2 years of initiation.
The incidence of SAMS varies with different statins
[28]. According to data from the PRIMO (Prediction of
Muscular risk in Observational) and STOMP (Effects of
Statins on Muscle Performance) studies, patients receiving
simvastatin or atorvastatin are reported to be at the highest
risk of SAMS (18.2 and 9.4–14.9 %, respectively) [40, 46];
patients receiving lovastatin might have a high risk of
SAMS [28]; and the lowest rates are described for patients
receiving pravastatin and fluvastatin (10.9 and 5.1 %,
respectively) [40].
One possible explanation for the low risk of myopathy
seen with pravastatin and fluvastatin may be because they
are more hydrophilic and hence have less muscle pene-
tration [28] (although this argument is weaker in the case of
fluvastatin, which is relatively lipophilic). However, they
are also least potent in LDL-C lowering, and statins asso-
ciated with more aggressive LDL-C lowering might be
expected to result in a higher risk of muscular adverse
effects [40, 47].
Higher incidences of rhabdomyolysis were reported
with atorvastatin or cerivastatin therapy, both as
monotherapy and in combination with fibrates [48]. This
was partially due to drug interactions with inhibitors of
P450 cytochrome (CYP) 3A4, the main CYP involved in
the hepatic metabolism of the lipophilic statins [49]. In
addition, several researchers have found that concurrent
use of statins with fibrates or niacin significantly increases
the risk of rhabdomyolysis compared with monotherapy,
with a higher risk more often reported in statin–fibrate
combinations than in statin–niacin combinations
[35, 37, 38]. These muscle effects have usually been
reported with the use of synthetic, potent, and more lipo-
philic statins [35, 37, 38].
An important consideration is the increased likelihood
of adverse effects with higher dose/potency statins. A
review by Golomb and Evans [50] summarized evidence
supporting a dose/potency dependence of statin adverse
effects (Table 1).
Despite treatment guideline recommendations, low
achievement rates of LDL-C targets are reported, and a
large proportion (10–20 %) of high-risk and very high-risk
patients still do not meet their target, particularly those who
are not receiving high-potency statins [39, 55, 56].
4 Familial Hypercholesterolaemia
FH is inherited as an autosomal dominant trait and is
characterized by markedly elevated circulating levels of
LDL-C from the time of birth as well as premature
atherosclerotic CVD (ASCVD) [57–59]. With a prevalence
of 1:200 [60] to 1:500 [61], heterozygous FH (HeFH) is
very common. LDL-C levels in these patients are two- to
threefold higher than normal [58, 59, 62, 63]. Homozygous
FH (HoFH) is very rare, affecting one in
300,000–1,000,000 individuals [57, 64]. The paucity or
even lack of any functional LDL receptors (LDLRs) leads
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to LDL-C levels that are three- to sixfold higher than
normal and a very early onset of atherosclerotic vascular
disease, frequently in childhood or adolescence
[58, 59, 62, 63]. Given the ASCVD complications associ-
ated with FH, reducing the burden of elevated LDL-C
levels is critical [57–60]. Novel well-tolerated therapeutic
strategies as add-ons to statin therapy, or as monotherapy in
cases of statin intolerance, are therefore essential in the
management of FH [60]. In patients with HeFH, LDL-C
target levels are frequently not reached via statins alone
because the baseline levels are very high. In patients with
HoFH with no residual LDLR function, statins do not
reduce LDL-C levels at all. In patients with HoFH with
little residual LDLR activity, only modest reductions
(10–25 %) in LDL-C serum concentrations are reached
even at the highest doses of the most efficacious statins
[58, 60]. These patients depend on extracorporeal LDL
elimination by apheresis.
5 Prevention of Cardiovascular Events
The ‘LDL hypothesis’ is a concept suggesting that it is the
reduction of LDL-C, regardless of the means (i.e. not just
via statins), that produces a corresponding reduction in
cardiovascular events [65]. An alternative theory, the
‘statin hypothesis’, postulates that statins have unique
efficacy in ASCVD that is not shared by other lipid-low-
ering agents and that LDL-C reduction is not the (only)
basis for the beneficial effects of statins [65]. Notably,
pleiotropic effects arising from the inhibition of 3-hydroxy-
3-methyl-glutaryl-CoA (HMG CoA) reductase, rather than
from LDL-C lowering, have been made responsible: inhi-
bition of HMG CoA reductase not only limits the pro-
duction of cholesterol, which is compensated by the
upregulation of LDLRs and hence LDL uptake, but also the
production of intermediary metabolites, which play
important regulatory roles, for example by prenylation of
many membrane proteins. This mechanism may explain
muscle toxicity at high systemic exposure.
Recent data from IMPROVE-IT (Improved Reduction
of Outcomes: Vytorin Efficacy International Trial)
emphasize the importance of LDL-C lowering as the pri-
mary strategy to prevent CHD [65]. After 7 years of fol-
low-up of 18,144 patients who had experienced an acute
coronary syndrome, the rate of the primary endpoint (a
composite of cardiovascular death, major coronary event
[non-fatal myocardial infarction, unstable angina, or non-
fatal stroke]) was 2 % lower in the combination therapy
group (simvastatin 40 mg plus ezetimibe 10 mg) than in
Table 1 Evidence of dose/potency dependence of statin adverse events (adapted from Golomb and Evans [50])
Study AE Comment
Silva et al. [51] (meta-analysis of RCTs) All AEs OR 1.44 (95 % CI 1.33–1.55; p\ 0.001) intensive- vs.
moderate-dose statin therapy
Silva et al. [51] (meta-analysis of RCTs) AEs leading to
treatment
discontinuation
OR 1.28 (95 % CI 1.18–1.39; p\ 0.001) intensive- vs.
moderate-dose statin therapy
Dale et al. [52] (meta-analysis of RCTs)
Silva et al. [51] (meta-analysis of RCTs)
CK elevation OR 6.12 (95 % CI 1.36–27.5) higher- vs. lower- dose statin
therapy (the odds appeared to be greater for lipophilic statins,
which have more muscle penetration)
OR 9.97 (95 % CI 1.3–77.9, p = 0.028) intensive- vs.
moderate-dose statin therapy
Dale et al. [52] (meta-analysis of RCTs)
Silva et al. [51] (meta-analysis of RCTs)
LFT elevation LFT (transaminase) elevation OR 2.7 (1.5–5.0) higher- vs.
lower- dose statin therapy (the effect appeared to be greater
for hydrophilic statins
LFT elevation (alanine or aspartate aminotransferase C3 times
the ULN) OR 4.5 (95 % CI 3.3–6.2) intensive- vs. moderate-
dose statin therapy
SEARCH Collaborative Group [53] (randomized trial of
12,064 pts who received simvastatin 20 or 80 mg
daily)
Rhabdomyolysis 49 cases of ‘definite myopathy’ in the simvastatin 80-mg group
vs. 2 in the simvastatin 20-mg group. 49 cases of ‘incipient
myopathy’ in the simvastatin 80-mg group vs. 6 in the
simvastatin 20-mg group
Golomb et al. [54] Non-CK elevating
muscle symptoms
Recurrence of statin AEs was significantly higher when pts
were rechallenged with same or higher potency statins vs.
rechallenge with a lower potency statins (*95 vs. 55 %,
p\ 0.01)
AE adverse effect, CI confidence interval, CK creatinine kinase, LFT liver function test, OR odds ratio, RCT randomized controlled trial, ULN
upper limit of normal
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the simvastatin monotherapy group (33 vs. 35 %) [66]. One
of the most important implications of this trial is that all
reductions in LDL-C levels by enhanced hepatic LDL
removal through the LDLR pathway are beneficial [65].
This is also suggested by the currently available outcome
data on proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors, which are discussed in section 6.2.
Further evidence in support of the causal role of LDL
and LDL-C in the pathogenesis of ASCVD has been
derived from Mendelian randomization (MR) studies. A
particular advantage of the MR approach is that it can
provide information on the impact of a lifetime modulation
of a biomarker [67]. In this respect, MR studies demon-
strated that frequent variants in the LDLR gene, which
increase LDL-C as early as in childhood by 15 mg/dl,
result in stronger effects on coronary artery disease risk
than predicted by epidemiological or clinical studies for
such a degree of LDL variability [68]. Conversely, indi-
viduals carrying a rare PCSK9 allele, which lowers LDL
way below population average (by 21–38 mg/dl), showed a
marked 40–80 % reduced incidence of myocardial infarc-
tion [69].
6 Alternative Treatment Options After Statin Use
When the maximally tolerated dose of statin therapy fails
to achieve the target LDL-C, clinicians need to consider
alternative and/or add-on second- and third-line options. In
these cases, combination therapy should be considered
[70].
6.1 Ezetimibe
Ezetimibe is the first lipid-lowering agent that inhibits
intestinal uptake of dietary and biliary cholesterol
without affecting the absorption of fat-soluble nutrients
[70]. The interrupted enterohepatic circulation and
enhanced fecal loss of cholesterol is compensated by
upregulation of LDLR and LDL uptake into the liver.
Combining ezetimibe with a statin (simvastatin) in
IMPROVE-IT reduced LDL-C by an additional 24 % in
stable patients who had experienced an acute coronary
syndrome [66]. In addition, the statin–ezetimibe combi-
nation can decrease LDL-C by 60–70 % in patients with
FH [60]. In view of the acceptable side-effect profile and
high compliance, the EAS recommends co-administra-
tion of ezetimibe as an add-on to statin therapy [60].
IMPROVE-IT [66], the first trial to demonstrate an
incremental clinical benefit from adding a non-statin
agent (ezetimibe) to statin therapy, found no significant
differences in rates of adverse events between the
combination therapy and monotherapy groups [65]. The
IMPROVE-IT findings are in line with data from an MR
study that found that mutations in NPC1L1 are associ-
ated with reduced levels of LDL-C and reduced risk of
ASCVD [71]. Together, the MR and trial data support
the ‘LDL hypothesis’ regarding reduction of cardiovas-
cular events in patients with cardiovascular risk factors.
6.2 Proprotein Convertase Subtilisin/Kexin Type 9
(PCSK9) Inhibitors
PCSK9 is a secreted protease that mediates LDLR degra-
dation (Fig. 1a) [57, 59, 72, 73]. Its important contribution
to the regulation of LDL-C levels was first demonstrated by
the identification of gain-of-function mutations of the
PCSK9 gene of patients with FH who had no mutations in
the LDLR or apolipoprotein-B (apoB) genes [69]. Addi-
tionally, individuals with loss-of-function mutations in
PCSK9 were found to have reduced plasma levels of LDL-
C and to be protected from CHD [69, 74].
Inhibition of PCSK9 has emerged as a new therapeutic
option. Three monoclonal antibodies are available: evolo-
cumab, alirocumab, and bococizumab.
The complementary mechanisms of action of statins,
PCSK9 and PCSK9 inhibitors are shown in Figs. 1 and 2.
Statins inhibit cholesterol biosynthesis, leading to
increased cellular sterol-regulatory element-binding pro-
tein-2 (SREBP-2) activity that promotes transcription of
SREBP-2-inducible LDLR and PCSK9 genes (Fig. 2).
However, this co-regulation is counteractive, as the pro-
duction of PCSK9 protein triggers LDLR protein traffick-
ing for lysosomal degradation and results in an attenuated
LDL-C-lowering effect of statins [75]. The introduction of
a PCSK9 inhibitor disrupts the interaction between PCSK9
and LDLR, raises LDLR protein, and increases LDL-C
lowering as compared with statins alone (Fig. 1b).
Evolocumab, alirocumab, and bococizumab are cur-
rently being studied in large clinical trial programs and
appear to be highly effective at reducing LDL-C levels,
achieving an additional 60–75 % reduction in patients
treated with statins. Importantly, no significant increase in
serious adverse events has been reported to date in phase
III trials, in particular, no increase in myotoxicity when
compared with statin-treated control patients [76].
In addition, small interfering RNAs—so-called antag-
omirs—have been developed to interfere with PCSK9
production in the liver. The previously published phase I
trial is the first example of therapeutic RNA interference in
humans [77].
Evolocumab PROFICIO Program PROFICIO (Pro-
gramme to Reduce LDL-C and Cardiovascular Outcomes
Following Inhibition of PCSK9 In Different Populations) is
a large and comprehensive clinical trial program evaluating
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evolocumab. The PROFICIO phase III program includes
14 trials, with a combined planned enrolment of more than
28,000 patients.
The phase III studies will evaluate subcutaneous
evolocumab 140 mg every 2 weeks and 420 mg monthly
in multiple patient populations, and four of the studies will
provide long-term safety and additional efficacy or cardio-
vascular outcome data. Table 2 summarizes the currently
available data from individual studies in patients with
unmet needs. The evidence from trials in these patients
indicates that evolocumab might be an efficacious and
tolerable option for them, a conclusion also drawn by Dadu
and Ballantyne [78] in their review of lipid lowering with
PCSK9 inhibitors.
In addition, in a pooled analysis of four phase III studies
(MENDEL-2, LAPLACE-2, RUTHERFORD-2, GAUSS-
2) that included 417 of 2729 patients with T2DM, the
efficacy and safety of evolocumab was comparable in
patients with or without T2DM and did not differ among
T2DM sub-groups [85]. These findings were confirmed
after 1 year of treatment in 4802 patients with, at high risk
for, or at low risk for, diabetes mellitus who had completed
one of 13 phase II or III parent studies of evolocumab
(OSLER-1 and OSLER-2). Patients were randomized to
receive either evolocumab 140 mg every 2 weeks or
420 mg monthly plus standard of care (SoC) or SoC alone
[86, 87]. Results were similar irrespective of parent-study
Fig. 1 Trafficking of LDLR in the presence of PCSK9 (a) or
following PCSK9 inhibition by a monoclonal antibody (b). a Secreted
PCSK9 binds to LDLR on the liver cell surface and mediates the
lysosomal degradation of the complex formed by PCSK9, LDLR, and
LDL [68]. b In the presence of a monoclonal antibody that binds to
PCSK9, the PCSK9-mediated degradation of LDLR is inhibited,
resulting in an increased uptake of LDL-cholesterol by LDLR as more
LDLR are recycled at the cell surface [72]. LDL low-density
lipoprotein, LDLR low-density lipoprotein receptor, PCSK9 propro-
tein convertase subtilisin/kexin type 9
Fig. 2 Impact of statins on cholesterol metabolism. Statins inhibit the
biosynthesis of intracellular cholesterol by inhibiting HMG-CoA
reductase. This results in low levels of intracellular cholesterol,
leading to increased SREBP-2 activity, which promotes the produc-
tion of PCSK9 and LDLR, the degradation of which is mediated by
PCSK9 [72]. HMG CoA 3-hydroxy-3-methyl-glutaryl-CoA, LDL low-
density lipoprotein, LDLR low density lipoprotein receptor, mRNA
messenger RNA, PCSK9 proprotein convertase subtilisin/kexin type
9, SREBP-2 sterol-regulatory element-binding protein
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Table 2 Summary of results from evolocumab trials in patient groups with unmet needs
Study Population Primary endpoints Efficacy Safety
GAUSS-2 [79]
(evolocumab vs.
ezetimibe)
Pts with hyperlipidemia
who cannot tolerate statin
therapy; N = 307
Percent change from
BL in LDL-C level
at the mean of
weeks 10 and 12,
and at week 12
Evolocumab reduced LDL-C
from BL by 53–56 %: tx
differences vs. ezetimibe of
37–39 % (p\ 0.001)
Muscle AEs: 12 % of
evolocumab-treated pts vs.
23 % of ezetimibe-treated
pts; TEAEs and laboratory
abnormalities comparable
across tx groups
RUTHERFORD-2
[80] (evolocumab vs.
PL)
Pts with HeFH, on
stable lipid-lowering
therapy; N = 329
Percent change from
BL in LDL-C level
at the mean of
weeks 10 and 12,
and at week 12
Evolocumab reduced mean
LDL-C at week 12 (every-2-
week dose: 59 % reduction,
monthly dose: 61 %
reduction; both p\ 0.0001)
and at the mean of week 10
and 12 (60 % reduction and
66 % reduction; both
p\ 0.0001)
Similar rates of AEs in both
groups, except for
nasopharyngitis (19 pts [9 %]
in the evolocumab group vs.
5 [5 %] in the PL group) and
muscle-related AEs (10 pts
[5 %] in the evolocumab
group vs. 1 [1 %] in the PL
group)
TESLA [81]
(evolocumab vs. PL)
Pts with HoFH, on
stable lipid-lowering
therapy; N = 49
Percentage change
from BL in
ultracentrifugation
LDL-C level at
week 12
Evolocumab reduced
ultracentrifugation LDL-C at
12 weeks by 31 %
(p\ 0.0001)
TEAEs occurred in 10 (63 %)
of 16 pts in the PL group and
12 (36 %) of 33 in the
evolocumab group
DESCARTES [82]
(evolocumab vs. PL)
Pts with hyperlipidemia
and a wide range of CV
risk, after a run-in period
of background lipid-
lowering therapy;
N = 901
Percent change from
BL in
ultracentrifugation
LDL-C level at
week 52
Overall LSM (±SE) reduction
in LDL-C 57 ± 2 % (taking
into account reduction in PL
group) (p\ 0.001); mean
reduction 56 ± 4 % in pts
with diet alone as background
therapy, 62 ± 3 % with
atorvastatin 10 mg,
57 ± 5 % with atorvastatin
80 mg, and 49 ± 5 % with
combination of atorvastatin
80 mg and ezetimibe 10 mg
(p\ 0.001 for all
comparisons)
Overall incidence of AE
occurring during tx was
similar in the evolocumab
and PL groups: 448 of 599
pts (75 %) vs. 224 of 302 pts
(74 %); most common AEs
in the evolocumab group:
nasopharyngitis, URTI,
influenza, and back pain
LAPLACE-2 [83]
(evolocumab vs.
ezetimibe and PL)
Pts at risk for CVD
receiving statin therapy;
N = 1899
Percent change from
BL in LDL-C level
at mean of weeks
10 and 12 and at
week 12
Evolocumab reduced LDL-C
levels by 66–75 % (every
2 weeks) and by 63–75 %
(monthly) vs. PL at mean of
weeks 10 and 12 in the
moderate- and high-intensity
statin-treated groups; LDL-C
reductions at week 12 were
comparable
AEs reported in 36 %, 40 %,
and 39 % of evolocumab-,
ezetimibe-, and PL-treated
pts, respectively; most
common AEs in evolocumab-
treated pts were back pain,
arthralgia, headache, muscle
spasms, and pain in extremity
(all\2 %)
TAUSSIG [84]
(evolocumab long-
term open-label;
interim results;
estimated
completion, January
2020)
Pts with HoFH, receiving
stable lipid-lowering
therapy; N = 100 (non-
apheresis, N = 66;
apheresis, N = 34)
Percentage change
from BL in LDL-C
at week 12
Evolocumab reduced LDL-C
in the overall cohort by 21 %
(p\ 0.05); reduction
maintained in the longer-term
(up to 48 weeks); in a subset
of non-apheresis pts, who
uptitrated to 420 mg every
2 weeks (N = 28), LDL-C
was reduced by a further 6 %
(p = 0.01)
Evolocumab was well-
tolerated
AE adverse effect, BL baseline, CV cardiovascular, CVD cardiovascular disease, HeFH heterozygous familial hypercholesterolaemia, HoFH
homozygous familial hypercholesterolaemia, LDL-C low-density lipoprotein cholesterol, LSM least squares mean, PL placebo, pt(s) patient(s),
SE standard error, TEAE treatment-emergent adverse effect, tx treatment, URTI upper respiratory tract infection
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drug assignment. Evolocumab showed encouraging safety,
with no measurable effect on skeletal muscle and glycemic
parameters despite reducing LDL-C levels markedly.
Alirocumab ODYSSEY Program The ODYSSEY phase
III program is expected to enroll more than 23,000 patients
and currently includes 12 clinical trials of alirocumab, both
in combination with other lipid-lowering agents and as
monotherapy in patients with primary HeFH or non-FH or
statin intolerance. Table 3 summarizes the currently
available data from individual studies in patients with
unmet needs. Similar to evolocumab, alirocumab appears
to be effective in lowering LDL-C and well-tolerated.
In a sub-analysis of 2341 patients with or without T2DM
from the ODYSSEY LONG TERM trial, the effects of
alirocumab were also shown to be consistent, regardless of
medical history of patients with T2DM at baseline [98].
Bococizumab SPIRE Program The bococizumab SPIRE
program is currently underway in phase III trials. Table 4
describes these, although no results are yet available.
PCSK9 inhibitors For statin-intolerant patients specifi-
cally, promising results of the efficacy of PCSK9 inhibitors
have already been shown in GAUSS 2 (Goal Achievement
After Utilizing an Anti-PCSK9 Antibody in Statin Intol-
erant Subjects—2) (evolocumab vs. ezetimibe) (see
Table 2); ODYSSEY ALTERNATIVE (alirocumab vs.
ezetimibe) (see Table 3). The ongoing GAUSS-3 trial is
the most recent statin intolerance study that incorporates a
double-blind, placebo-controlled statin rechallenge prior to
a 6-month evolocumab versus ezetimibe comparison, with
a 2-year open-label extension. Further evidence will come
from outcome trials; for now, LDL-C is an accepted mar-
ker for lipid-lowering therapies, and these data should be
used for future guideline updates [104].
In conclusion, the available data on efficacy and
safety of both evolocumab and alirocumab look very
encouraging. Firm evidence will be obtained by clinical
outcome trials that will be concluded in the near future
[105, 106].
In 2015, evolocumab and alirocumab have received
marketing authorization in the EU and the USA (Table 5).
Despite their broad indications, the cost of monoclonal
antibodies may restrict the use of PCSK9 inhibitors to
patients with high LDL-C, where statins are not efficient
enough, and to patients intolerant to statins, for whom these
new treatment options may be the most cost effective
[76, 107]. The substantial potential health benefits and
savings in healthcare costs from preventing CHD events
will need to be weighed against the possibility of adverse
effects of long-term statin therapy and the costs of alter-
native treatments.
6.3 Other Statin Alternatives
Novel potent LDL-C-lowering therapies currently under
investigation include mipomersen, an apoB synthesis
inhibitor [110–115], and lomitapide, a microsomal
triglyceride transfer protein (MTP) inhibitor [116–119].
Unlike statins or PCSK9 inhibitors, which ultimately
lower LDL-C by increasing LDLR expression in the
liver and hence hepatic clearance of LDL-C, mipom-
ersen and lomitapide inhibit the production of chy-
lomicrons, very low-density lipoprotein (VLDL), and
LDL. Independence of the LDLR makes these two
regimens particularly applicable for the treatment of
HoFH. However, the prevention of VLDL production
increases hepatic fat accumulation. Consequently,
mipomersen (only in the USA) and lomitapide (in the
USA and Europe) are currently authorized for treatment
of HoFH only.
Cholesteryl ester transfer protein (CETP) transfers
cholesterol esters from HDL to LDL. Patients with CETP
deficiency have high levels of HDL-C and low levels of
LDL-C. CETP inhibitors have been developed, five of
which have been or currently are in different stages of
clinical investigation [120]. Whereas dalcetrapib only
increased HDL-C levels, torcetrapib (ILLUMINATE trial)
[121], anacetrapib (DEFINE trial) [122], evacetrapib [123],
and TA-8995 (TULIP trial) [124] also caused 14–45 %
decreases in LDL-C. However, clinical endpoint trials on
torcetrapib, dalcetrapib, and evacetrapib have been stopped
prematurely because of excess rates of serious adverse
events (torcetrapib) or futility (dalcetrapib, evacetrapib).
The anacetrapib phase III trial was very recently
announced to be continued.
Other therapies, such as bile acid sequestrants and
nicotinic acid, have been evaluated but found to be poorly
tolerated [79]. Furthermore, the addition of niacin to statins
did not further decrease major adverse cardiac event rates
in the AIM-HIGH trial [125]. Consequently, niacin is no
longer available in Europe.
7 Controversies About Sub-Normally Low LDL-C
Levels
The beginning of cholesterol-lowering therapy in the 1980s
witnessed a fierce discussion on the harm of low
cholesterol.
Cholesterol is a natural component of the body’s
metabolism: together with other lipids, it is an essential
constituent of cell membranes and a constituent of steroid
hormones, vitamin D, and bile acids [126]. Cholesterol is
also an indispensable component of cell membranes in the
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brain [126]. Interestingly, there have been reports of higher
all-cause mortality in populations with sub-normally low
cholesterol levels [126]. For example, MRFIT (Multiple
Risk Factor Intervention Trial) and other older studies
suggested increased mortality of malignant and other dis-
orders in individuals with serum cholesterol\3.6 mmol/l
(140 mg/dl) [126, 127]. However, this association may
result from reverse causality: individuals with low
cholesterol may have pre-clinical severe diseases that
decrease cholesterol levels. After adjustment for body
weight and smoking, the J-shaped relationship between
cholesterol and total mortality disappeared. Moreover,
25 years of trial experience with statins do not indicate any
increase in risk for serious life-threatening or life expec-
tancy-limiting disease [126].
Nevertheless, the advent of very effective combination
therapies for LDL-C lowering will revive the discussion on
the potential threats from very low cholesterol levels.
Innate errors of metabolism may give some information in
this regard. Many carriers of loss-of-function mutations in
PCSK9 or angiopoietin-like protein type 4 (ANGPTL4), as
well as carriers of mutations preventing the synthesis of
full-length apoB, have very low levels of LDL-C. These
conditions are not known to limit the life expectancy or
quality of life of their carriers. Quite the opposite, they
appear to dramatically reduce the risk of myocardial
infarction [128, 129]. Only patients with homozygous
hypobetalipoproteinemia and patients with abetalipopro-
teinemia (because of mutations in MTP) with complete
absence of apoB-containing lipoproteins experience severe
neurological disease such as ataxia and retinitis pigmentosa
[130].
The adverse effects of extreme LDL-C lowering can be
subclinical and overlooked for a long time. Thus, the
increased risk of diabetes with statin treatment has been
uncovered only recently, after 20 years of prior statin use.
Initial data also point to increased loss of bone mass with
statin treatment. However, the mechanism and hence
extrapolation of the finding to non-statin interferences and
LDL-C lowering in general is controversial. Some authors
suggested that statins affect insulin secretion in beta cells
as well as insulin signaling in peripheral target organs by
interfering with the synthesis of bioactive intermediates in
the mevalonate–cholesterol pathway [131, 132]. In this
Table 4 Phase III bococizumab trials (ongoing)
Study Population Comparison Estimated
completion
SPIRE-HF [99] https://clinicaltrials.gov/
ct2/show/NCT01968980
Pts with HeFH with high and very high CVD
risk (with statin therapy)
Bococizumab vs. PL at 12 weeks January 2016
SPIRE-HR [100] https://clinicaltrials.gov/
ct2/show/NCT01968954
Pts with high and very high CVD risk (with
statin therapy)
Bococizumab vs. PL at 12 weeks January 2016
SPIRE-LDL [101] https://clinicaltrials.
gov/ct2/show/NCT01968967
Pts with high and very high CVD risk (with
statin therapy)
Bococizumab vs. PL at 12 weeks December
2015
SPIRE-1 [102] https://clinicaltrials.gov/
ct2/show/NCT01975376
Pts with high and very high CVD risk (with
lipid-lowering therapy)
Bococizumab vs. PL at 5 years
(effects on major CV events)
August 2017
SPIRE-2 [103] https://clinicaltrials.gov/
ct2/show/NCT01975389
Pts with high and very high CVD risk (with
lipid-lowering therapy)
Bococizumab vs. PL at 5 years
(effects on major CV events)
August 2017
CV cardiovascular, CVD cardiovascular disease, HeFH heterozygous familial hypercholesterolemia, PL placebo
Table 5 PCSK9 inhibitors approved in Europe and the USA
PCSK9 inhibitor Indications
Evolocumab [108]
(evolocumab SmPC)
Adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as
an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in pts unable to
reach LDL-C goals with the maximum tolerated dose of a statin or alone or in combination with other lipid-
lowering therapies in pts who are statin intolerant or for whom a statin is contraindicated
Adults and adolescents aged C12 years with homozygous FH in combination with other lipid-lowering
therapies
Alirocumab [109] (alirocumab
SmPC)
Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia as
an adjunct to diet: in combination with a statin or statin with other lipid-lowering therapies in pts unable to
reach LDL-C goals with the maximum tolerated dose of a statin or alone or in combination with other lipid-
lowering therapies in pts who are statin intolerant or for whom a statin is contraindicated
FH familial hypercholesterolemia, LDL-C low-density lipoprotein cholesterol, pt(s) patient(s), SmPC summary of product characteristics
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case, non-statin mediated LDL-C lowering may not be
diabetogenic. Others showed that LDL interferes with
insulin secretion in an LDLR-dependent manner
[133, 134], and that patients with FH are at reduced risk of
diabetes [135]. In that case, non-statin interventions that
upregulate the LDLR in pancreatic beta cells may also be
diabetogenic.
However, follow-up of whether these changes in inter-
mediary phenotypes lead to adverse clinical outcomes will
be required. With respect to diabetes, it is important to
highlight that statins reduce coronary event rates as well as
the incidence of diabetic nephropathy.
Nonetheless, these examples indicate an urgent need to
closely monitor the efficacy and safety of novel choles-
terol-lowering regimens, such as PCSK9 inhibitors. For
safety, it will be important to use methods that objectively
measure specific endpoints, such as cognitive and other
brain functions.
8 Conclusions
Statins are currently the SoC in the management of dys-
lipidemia. Treatment guidelines recommend optimization
of statin dose when patients do not reach LDL-C targets.
However, treatment aims may not be reached with statins
in many patients at high risk of cardiovascular events, such
as patients with FH or statin intolerance. Such patients
require more effective treatment options and may benefit
from combination therapy with ezetimibe or a PCSK9
inhibitor. PCSK9 inhibitors are now available, and treat-
ment guidelines need to be updated to guide the manage-
ment of patients who will best benefit from these new
treatments.
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